{
    "organizations": [],
    "uuid": "1cbf10fa987c937837b52d9685a2edc10feb444c",
    "author": "",
    "url": "https://www.reuters.com/article/brief-beigene-announces-commercial-avail/brief-beigene-announces-commercial-availability-of-vidaza-in-china-idUSFWN1PV1F0",
    "ord_in_thread": 0,
    "title": "BRIEF-BeiGene Announces Commercial Availability Of Vidaza In China",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "February 5, 2018 / 11:08 PM / in 10 minutes BRIEF-BeiGene Announces Commercial Availability Of Vidaza In China Reuters Staff \nFeb 5 (Reuters) - BeiGene Ltd: \n* BEIGENE ANNOUNCES COMMERCIAL AVAILABILITY OF VIDAZAÂ® (AZACITIDINE FOR INJECTION) IN CHINA \n* BEIGENE LTD - VIDAZA IS MARKETED IN CHINA BY BEIGENE UNDER AN EXCLUSIVE LICENSE FROM CELGENE CORPORATION Source text for Eikon: Further company coverage:",
    "published": "2018-02-06T01:06:00.000+02:00",
    "crawled": "2018-02-06T01:23:57.006+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "february",
        "pm",
        "minute",
        "announces",
        "commercial",
        "availability",
        "vidaza",
        "china",
        "reuters",
        "staff",
        "feb",
        "reuters",
        "beigene",
        "ltd",
        "beigene",
        "announces",
        "commercial",
        "availability",
        "azacitidine",
        "injection",
        "china",
        "beigene",
        "ltd",
        "vidaza",
        "marketed",
        "china",
        "beigene",
        "exclusive",
        "license",
        "celgene",
        "corporation",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}